SEC Form 4 · accession 0001193125-26-285562
Definium Therapeutics, Inc. · DFTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Barrow
Officer — Chief Executive Officer · Director
Period of report
Jun 25, 2026
Accepted (ET)
Jun 26, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001813814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jun 25, 2026 | S | 29,208 | $45.03 | D | 1,098,246 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022.